Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 7/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15777271 | 0.92 | USP2 (0.41) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL21590661 | 0.92 | USP2 (0.41) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL21590800 | 0.92 | USP2 (0.41) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL15776899 | 0.82 | USP2 (0.41) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL30694887 | 0.80 | USP2 (0.41) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL30694891 | 0.80 | USP2 (0.41) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL30922555 | 0.80 | HPGD (0.40) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL20411385 | 0.79 | USP2 (0.46) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL897951 | 0.79 | USP2 (0.46) | USP2SMN1; SMN2CHRM2CHRM1CHRM3 | |
| SCHEMBL17973605 | 0.79 | USP2 (0.40) | USP2SMN1; SMN2EPHX2RORCRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | HOFFMANN-LA ROCHE INC. (US) | 2023-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230135093-A1 | TRIAZOLYL DERIVATIVES AS GABA A ALPHA5 PAM | GABRA5, GABRA3, GABRB3 | USP2 3724/4885SMN1; SMN2 2373/4885CHRM2 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.